Application 761083

Type
BLA
Sponsor
GENENTECH INC

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761083Hemlibraemicizumab-kxwh351(a)Rx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001HEMLIBRAEMICIZUMABINJECTABLE;INJECTION30MG/MLYesNo
002HEMLIBRAEMICIZUMABINJECTABLE;INJECTION60MG/0.4MLYesNo
003HEMLIBRAEMICIZUMABINJECTABLE;INJECTION105MG/0.7MLYesNo
004HEMLIBRAEMICIZUMABINJECTABLE;INJECTION150MGYesNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HemlibraEMICIZUMABGenentech, Inc.2483adba-fab6-4d1b-96c5-c195577ed0712025-07-11Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761083
ndc (product): 50242-920
ndc (product): 50242-922
ndc (product): 50242-923
ndc (product): 50242-921

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 28 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-920HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-921HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-922HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent
50242-923HemlibraemicizumabGenentech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
82782SUPPL 2025-07-11
82781SUPPL 2025-07-11
82763SUPPL 2025-07-09
77391SUPPL 2024-02-02
77382SUPPL 2024-02-01
71864SUPPL2022-08-23
71863SUPPL2022-08-23
71232SUPPL2022-06-07
69709SUPPL2021-12-21
69623SUPPL2021-12-17
69622SUPPL2021-12-17
68582SUPPL2021-09-10
68581SUPPL2021-09-10
68547SUPPL2021-09-07
55885SUPPL2018-10-11
55884SUPPL2018-10-11
55810SUPPL2018-10-04
55809SUPPL2018-10-04
55808SUPPL2018-10-04
55807SUPPL2018-10-04
50944ORIG2017-12-29
50444ORIG2017-11-17
50432ORIG2017-11-16